These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16678413

  • 1. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
    Thomas SA, Li T, Woods KW, Song X, Packard G, Fischer JP, Diebold RB, Liu X, Shi Y, Klinghofer V, Johnson EF, Bouska JJ, Olson A, Guan R, Magnone SR, Marsh K, Luo Y, Rosenberg SH, Giranda VL, Li Q.
    Bioorg Med Chem Lett; 2006 Jul 15; 16(14):3740-4. PubMed ID: 16678413
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD, Gong J, Gandhi VB, Woods K, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Stoll VS, Mamo M, Li Q, Rosenberg SH, Giranda VL.
    Bioorg Med Chem; 2007 Mar 15; 15(6):2441-52. PubMed ID: 17258463
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q, Woods KW, Thomas S, Zhu GD, Packard G, Fisher J, Li T, Gong J, Dinges J, Song X, Abrams J, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Des Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):2000-7. PubMed ID: 16413780
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, Olson AM, de Jong R, Oltersdorf T, Luo Y, Rosenberg SH, Giranda VL, Li Q.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6832-46. PubMed ID: 16843670
    [Abstract] [Full Text] [Related]

  • 7. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2194-7. PubMed ID: 18294842
    [Abstract] [Full Text] [Related]

  • 8. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q, Li T, Zhu GD, Gong J, Claibone A, Dalton C, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Bauch JL, Marsh KC, Bouska JJ, Arries S, De Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Mar 15; 16(6):1679-85. PubMed ID: 16403626
    [Abstract] [Full Text] [Related]

  • 9. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Stoll VS, De Jong R, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3150-5. PubMed ID: 16603355
    [Abstract] [Full Text] [Related]

  • 10. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
    Kendall JD, O'Connor PD, Marshall AJ, Frédérick R, Marshall ES, Lill CL, Lee WJ, Kolekar S, Chao M, Malik A, Yu S, Chaussade C, Buchanan C, Rewcastle GW, Baguley BC, Flanagan JU, Jamieson SM, Denny WA, Shepherd PR.
    Bioorg Med Chem; 2012 Jan 01; 20(1):69-85. PubMed ID: 22177405
    [Abstract] [Full Text] [Related]

  • 11. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
    Byth KF, Culshaw JD, Green S, Oakes SE, Thomas AP.
    Bioorg Med Chem Lett; 2004 May 03; 14(9):2245-8. PubMed ID: 15081017
    [Abstract] [Full Text] [Related]

  • 12. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
    Kendall JD, Giddens AC, Tsang KY, Frédérick R, Marshall ES, Singh R, Lill CL, Lee WJ, Kolekar S, Chao M, Malik A, Yu S, Chaussade C, Buchanan C, Rewcastle GW, Baguley BC, Flanagan JU, Jamieson SM, Denny WA, Shepherd PR.
    Bioorg Med Chem; 2012 Jan 01; 20(1):58-68. PubMed ID: 22177407
    [Abstract] [Full Text] [Related]

  • 13. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
    Murphy ST, Alton G, Bailey S, Baxi SM, Burke BJ, Chappie TA, Ermolieff J, Ferre R, Greasley S, Hickey M, Humphrey J, Kablaoui N, Kath J, Kazmirski S, Kraus M, Kupchinsky S, Li J, Lingardo L, Marx MA, Richter D, Tanis SP, Tran K, Vernier W, Xie Z, Yin MJ, Yu XH.
    J Med Chem; 2011 Dec 22; 54(24):8490-500. PubMed ID: 22040023
    [Abstract] [Full Text] [Related]

  • 14. Rapid assembly of diverse and potent allosteric Akt inhibitors.
    Wu Z, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Kohl NE, Hartman GD, Bilodeau MT.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2211-4. PubMed ID: 18296048
    [Abstract] [Full Text] [Related]

  • 15. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
    Jaramillo C, de Diego JE, Hamdouchi C, Collins E, Keyser H, Sánchez-Martínez C, del Prado M, Norman B, Brooks HB, Watkins SA, Spencer CD, Dempsey JA, Anderson BD, Campbell RM, Leggett T, Patel B, Schultz RM, Espinosa J, Vieth M, Zhang F, Timm DE.
    Bioorg Med Chem Lett; 2004 Dec 20; 14(24):6095-9. PubMed ID: 15546737
    [Abstract] [Full Text] [Related]

  • 16. Design and synthesis of novel amide AKT1 inhibitors with selectivity over CDK2.
    Ashton KS, St Jean DJ, Poon SF, Lee MR, Allen JG, Zhang S, Lofgren JA, Zhang X, Fotsch C, Hungate R.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5191-6. PubMed ID: 21824779
    [Abstract] [Full Text] [Related]

  • 17. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA, Lapierre JM, Brassard C, Bresciano K, Bull C, Cornell-Kennon S, Eathiraj S, France DS, Hall T, Hill J, Kelleher E, Khanapurkar S, Kizer D, Koerner S, Link J, Liu Y, Makhija S, Moussa M, Namdev N, Nguyen K, Nicewonger R, Palma R, Szwaya J, Tandon M, Uppalapati U, Vensel D, Volak LP, Volckova E, Westlund N, Wu H, Yang RY, Chan TC.
    J Med Chem; 2012 Jun 14; 55(11):5291-310. PubMed ID: 22533986
    [Abstract] [Full Text] [Related]

  • 18. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.
    Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME.
    Bioorg Med Chem Lett; 2005 Feb 01; 15(3):761-4. PubMed ID: 15664853
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM.
    J Med Chem; 2003 Oct 23; 46(22):4702-13. PubMed ID: 14561090
    [Abstract] [Full Text] [Related]

  • 20. The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1).
    Nittoli T, Dushin RG, Ingalls C, Cheung K, Floyd MB, Fraser H, Olland A, Hu Y, Grosu G, Han X, Arndt K, Guo B, Wissner A.
    Eur J Med Chem; 2010 Apr 23; 45(4):1379-86. PubMed ID: 20074837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.